Background and aim: Precore (PC) and basal core promoter (BCP) mutations are associated with responses to interferon-based treatment in HBeAg-positive chronic hepatitis B (CHB) patients. Here, we identify viral minority variants in these regions and assess association with response to peginterferonalfa (Peg-IFN) and adefovir combination therapy. Patients and methods: Ultra-deep pyrosequencing analysis of the BCP and PC region was performed for 89 CHB patients (42 HBeAg-positive; 47 HBeAg-negative), at baseline and during treatment. Specifically, associations of individual positions with the HBeAg-negative phenotype were studied, as well as the association of the most prevalent mutations with combined response in HBeAg-positive and enegative patients at week 72 (HBeAg negativity, HBV-DNA <2000 IU/mL and ALT normalization at 24 weeks of treatment-free follow-up). Results: The mutations most strongly correlated with the HBeAg-negative phenotype were at positions 1762/1764 and 1896/1899 in the BCP and PC region, respectively. No major changes in nucleotide composition of these positions were observed during treatment. In HBeAg-negative patients, a combined presence of 1764A and 1896A was correlated with lower ALT levels (p ¼ 0.004), whereas the presence of 1899A was correlated with higher age (p ¼ 0.030), lower HBV-DNA level (p ¼ 0.036), and previous IFN therapy (p ¼ 0.032). The presence of 1764A/1896A or the absence of 1899A at baseline, was associated with lower response rates, after adjustment for HBV genotype (p ¼ 0.031 and p ¼ 0.017) and HBsAg level (p ¼ 0.035 and p ¼ 0.022). Conclusion: We identified novel correlations between common BCP and PC variants with response to Peg-IFN and adefovir in HBeAg-negative patients. Ultimately, this may guide the selection of those patients most likely to benefit from Peg-IFN-based treatment.
Introduction
Prolonged hepatitis B virus (HBV) infection increases the risk of liver-related morbidity and mortality, including liver cirrhosis and hepatocellular carcinoma (Amin et al., 2006) . Chronic hepatitis B (CHB) patients with a high viral load and active liver inflammation can currently be treated with either nucleos(t)ide analogues (NUCs) or pegylated-interferon alfa-2a (Peg-IFN) (European Association for the Study of the L, 2012; Lok and McMahon, 2009) .
While NUCs potently reduce HBV-DNA and its associated complications (Marcellin et al., 2013) , the HBV covalently closed circular DNA (cccDNA) within hepatocytes remains transcriptionally active, and discontinuation of NUCs usually results in recurrence of disease activity. In contrast, treatment with Peg-IFN can lead to a sustained off-treatment viral suppression in a subgroup of patients, but is associated with significant side-effects. Attempts to achieve improved outcomes with Peg-IFN and NUC combination therapy have been disappointing when lamivudine was included (Janssen et al., 2005; Lau et al., 2005; Marcellin et al., 2004) . Despite this, the use of Peg-IFN with more potent NUCs remains of interest because of their proven differential effects on the innate and adaptive immune responses (Thimme and Dandri, 2013) . Indeed, more recent studies show a benefit of Peg-IFN þ NUC combination therapy, compared to both monotherapies (Brouwer et al., 2015; Marcellin et al., 2014) . In addition, in our previously conducted study with a combination of peginterferon and adefovir a relatively high rate of HBsAg loss (11e17% at year 2) was observed, most specifically in HBeAg-negative patients (Takkenberg et al., 2013) .
Nevertheless, the majority of patients are still treated without achieving a satisfactory outcome. It is therefore crucial to identify those patients who will benefit from Peg-IFN based treatment before the start of therapy, avoiding unnecessary use of this medication in patients with low chance of response. Previous research suggested several potential virus and host characteristics that were associated with response to treatment, including specific mutations in the viral genome.
The most extensively studied mutations in the HBV genome are those located in the precore (PC) and basal core promoter (BCP) region. Mutations in these regions have been implicated in reducing Hepatitis B e antigen (HBeAg) production and hence strongly associate with the HBeAg-negative status.
The most well-described PC mutation comprises a G-A substitution at nucleotide position 1896 of the HBV genome, creating a premature stop codon in the precore open reading frame which abrogates HBeAg synthesis. The proposed function of this mutation is related to its location in the encapsidation (ε) signal, which forms a secondary stem-loop structure of the RNA pregenome that is essential for the initiation of encapsidation of the pregenome (Lok et al., 1994) . In the stem-loop, G1896A restores base pairing with T1858 leading to enhanced stability of this secondary structure (Lok et al., 1994) . Similarly, the G1899A mutation further enhances the stability by base pairing with T1855.
In contrast, a cytosine (C) is present at position 1858 in HBV genotype A, F and some genotype C strains, making G1896 changes rare. In these patients mutations in the BCP region are preferably selected, whereas in other patients BCP mutations can be observed in conjunction with PC mutations (Chan et al., 1999) . The most common BCP mutations, A1762T and G1764A, result in reduced HBeAg synthesis by influencing precore RNA transcription (Parekh et al., 2003; Buckwold et al., 1996) .
Mutations in the PC and BCP region have previously been shown to influence IFN-based therapy response. Various studies, both with conventional IFN and Peg-IFN, associated an increased frequency of PC or BCP mutations with treatment-induced HBeAg seroconversion (Tseng et al., 2011; Chen et al., 2011; Tangkijvanich et al., 2009; Marrone et al., 2003; Erhardt et al., 2000) . In contrast, a more recent study stated that the presence of BCP or PC mutations actually limits the probability of a sustained off-treatment (combined serological and virological) response to Peg-IFN (Sonneveld et al., 2012) .
Importantly, data on the effect of PC and BCP mutations on IFNresponse is limited to HBeAg-positive patients. Furthermore, HBV variants that coexist as minorities with wild-type strains may have been missed in previous studies since they were mostly performed with less sensitive direct sequencing methods. Next-generation sequencing techniques, based on ultra-deep pyrosequencing (UDPS), generate vast quantities of data and allow the quantitative analysis of mutant and wild-type species <1% (Eriksson et al., 2008) . So far, UDPS data in HBV is limited to studies on HBeAg seroconversion in the natural history or resistance in nucleos(t)ide analogue treated patients (Homs et al., 2014; Rodriguez et al., 2013; Nishijima et al., 2012; Margeridon-Thermet et al., 2009) .
Here, we studied mutations in the PC and BCP region in a wellcharacterized cohort of 89 chronic hepatitis B patients (42 HBeAgpositive; 47 HBeAg-negative) treated with a combination of Peg-IFN and adefovir. We aimed to shed new light on this wellstudied region by analyzing mutational patterns quantified by UDPS both before and during treatment, and associate these with therapy response.
Patients and methods

Subjects
In total, 92 CHB patients with HBV-DNA levels above 100,000 copies/mL (17,182 IU/mL) participated in a prospective investigatorinitiated study, of which detailed study characteristics have been described elsewhere (Takkenberg et al., 2013) . In summary, patients were treated for 48 weeks with peginterferon alfa-2a 180 mg subcutaneously once a week, and adefovir dipivoxil 10 mg daily. After 48 weeks, treatment was discontinued and a treatment-free follow-up period started. The study was conducted according to the guidelines of the Declaration of Helsinki, with the principles of Good Clinical Practice and was approved by local ethics committees (controlled-trials.com; ISRCTN 77073364). All patients gave written informed consent.
Of the 92 patients treated in the initial study, 89 had baseline plasma samples available for sequencing analysis (Fig. 1) . In addition, 84/89 patients completed 48 weeks of treatment and 2 years of follow-up, and comprised the per-protocol population to study associations with treatment response.
Achievement of a combined response (CR) and/or HBsAg loss (HBsAg<0.05 IU/mL) was determined after 24 weeks (week 72) and 2 years (week 144) of treatment-free follow-up. Combined response was defined as HBV-DNA levels 2000 IU/mL and persistent normal alanine aminotransferase (ALT) levels in both HBeAg-positive and -negative patients, including HBeAg loss in HBeAg-positive patients (European Association for the Study of the L, 2012).
Sample selection
For each patient a pre-treatment (baseline) plasma sample was subjected to both Sanger sequencing and 454 deep sequencing. In addition, an on-treatment sample was selected at Week 12 or at the latest time-point where the viral load was >10,000 IU/mL. Median sampling time of this second time-point was 12 weeks (iqr 6.1e24.0) for HBeAg-positive patients, and 1.6 weeks (iqr 0.6e4.0) for HBeAg-negative patients ( Supplementary Fig. S1 ). Mean HBV-DNA levels at the second time-point were 3.94 (±0.61) and 3.52 (±0.63) log 10 IU/mL, respectively.
Sanger sequencing
Sanger sequencing of the HBV genome was performed at DDL diagnostic laboratory (Rijswijk, The Netherlands). HBV DNA was isolated from 200 mL of plasma by the MagNA Pure LC instrument, using the Total Nucleic Acid isolation kit (Roche Applied Science). The complete HBV genome was amplified by PCR, using the Expand High Fidelity kit (Roche), with the use of primers developed by DDL. Details on DNA amplification, PCR reactions and sequence assembly and analysis are available upon request.
454 deep sequencing
DNA extracted from plasma as described above was additionally used in a full HBV genome amplification, in an overlapping amplicon approach, using degenerative PCR fusion primer sets to cover the HBV genome. For full genome coverage 13 separate amplicons were generated with an average length of 400 nucleotides each. The BCP and PC region located between positions 1613 and 1908 in the core promoter and precore region was covered by 2 amplicons as indicated in Supplementary Fig. S2 (remaining primer sequences available upon request). The obtained PCR fragments were subjected to deep sequencing using the Roche 454 platform according to the manufacturer's instructions. The entire workflow of PCR and 454 sequencing was performed by 454 Life Sciences, Branford CT.
Data analysis
Data analysis was performed in a stepwise fashion. Briefly, primer sequences were removed by trimming the first and last 30 nucleotides of each sequence read followed by removal of low quality nucleotides (phred < 28) from the 3 0 read end. Subsequently, final read quality was checked using the quality control function from QUASR v.7.0.1 (with setting em 33 and el 50). Next, all trimmed and quality controlled reads were aligned to genotype specific reference sequences (taxonomy ID's: AF297621 (A1), X02763 (A2), D00330 and AB073858 (B), AB033556 (C), X02496 (D), X75657 (E)), using the bwasw mapping option of the BurrowsWheeler Aligner (BWA) version 0.6.1-r104 with default settings. From the resulting sequencing alignment map (SAM) file coverage overviews per reference sequence position were generated disregarding nucleotides with a phred score below 30. Amino acid variation per position was determined disregarding codons containing >1 nucleotide with a phred <20. Amino acid positions covered by primers used in the PCR amplification process were discarded in further analysis.
Statistical analysis
From the multiple sequence alignment generated by 454 DS, a position profile was obtained which contained nucleotide distributions for each nucleotide position. In further analyses we focused on nucleotides located between positions 1613 and 1908 in the core promoter and precore region.
First, position profiles were used to calculate the root-meansquared deviation (RMSD) values for each nucleotide, in order to assess differences in nucleotide composition between HBeAgpositive and enegative patients (Li et al., 2010) . This evaluation was stratified by the presence of a C or T at position 1858. Second, positions most strongly associated with HBeAg negativity (indicated by highest RMSD values) were selected to study associations with baseline characteristics and therapy response.
To assess the association of core promoter and precore mutations with response, in relation to other baseline variables, multivariable logistic regression was applied. To prevent overfitting due to inclusion of too many variables with a limited sample size, we analyzed the effect of two important possible confounding factors (HBsAg and HBV genotype D) in two separate models. No significant multicollinearity between variables was observed. Classification accuracy was derived from the classification table. The improvement for model 1 and 2 was calculated based on the change in À2 Log likelihood compared to a model comprising only HBV genotype D or baseline HBsAg, respectively. Two-sided p-values <0.05 were considered statistically significant. Statistical comparisons were performed using IBM SPSS Statistics, v23 (SPSS Inc., IL, USA).
Results
Patient characteristics
Baseline characteristics of all patients (n ¼ 89) included in this study are summarized in Table 1 . Patients were HBeAg-positive (n ¼ 42) or HBeAg-negative (n ¼ 47), and had HBV genotypes A (n ¼ 28), B (n ¼ 15), C (n ¼ 12), D (n ¼ 25), or E (n ¼ 9). A phylogenetic tree of the consensus HBV sequences from individual patients is shown in Supplementary Fig. S3 .
In total, 84 patients completed the treatment and follow-up and comprised the per-protocol population used for studying associations with treatment response. At week 72, 30/84 patients (36%) had a combined response. After 2 years of treatment-free follow-up (week 144), 13 patients had achieved HBsAg loss (15%), of whom all but one had developed anti-HBs. The other patient developed antiHBs at week 177 (Takkenberg et al., 2013) .
HBeAg status and core promoter/precore variability
The differences in nucleotide composition of the core promoter and precore region (nucleotides 1613e1908) between HBeAgpositive and enegative patients was determined by calculating the RMSD value for each position. This excluded 12 positions (1821e1832) with a mean sequence coverage <1000 reads as a result of start/stop positioning of amplification primers ( Supplementary Fig. S2 ).
The mutations most strongly associated with the HBeAgnegative phenotype in patients with a C at position 1858 were located in the basal core promoter: RMSD 0.194 and 0.218 for positions 1762 and 1764, respectively (Fig. 2) . For patients with a T at position 1858 highest RMSD values were found for mutations in the precore region at position 1896 and 1899: 0.217 and 0.131, respectively (Fig. 2) .
Mutations at other positions had either low RMSD values (<0.10) or were restricted to genotype A (position 1850) or subgenotype A1 (position 1740).
In all but one HBeAg-negative patient with C1858, a full mutation (>99% non-reference) was present in BCP position 1762 and/or 1764. None of these patients had the 1762 mutation without the 1764 mutation, and none of these patients harbored the G1896A mutation. In contrast, all HBeAg-negative patients with T1858 had a non-reference majority at PC position 1896 (Fig. 3) . In total, 31/35 HBeAg-negative patients with T1858 had a full mutation (>99%) at position 1896, compared to 0/22 HBeAg-positive patients with T1858 (Fig. 3) .
Comparison with Sanger sequencing results
Overall, there was a good agreement between 454 DS and Sanger sequencing for positions 1762, 1764, 1896, and 1899 (Unweighted Kappa 0.98 ± 0.01 for detecting reference and nonreference nucleotides). Positions with a mutation detected by Sanger sequencing were all identified as positions with a mutation by 454 DS as well (n ¼ 105/105, mean % non-reference 0.98, SD 0.07). The majority of positions with a reference nucleotide by Sanger sequencing had a reference consensus nucleotide by 454 DS (n ¼ 168/170, mean % non-reference 0.02, SD 0.09).
However, in 20.7% of the non-ambiguous nucleotide calls (n ¼ 57/275) a minor population of >1% identified by 454 DS was missed by Sanger sequencing (Supplementary Fig. S4 ). In contrast, in most ambiguous nucleotide calls by Sanger sequencing a minor population of >1% at this position was found by 454 DS as well (n ¼ 21/23, mean % non-reference 0.51, SD 0.28).
On-treatment kinetics of core promoter/precore variability
For each patient the proportion of non-reference nucleotides at baseline (T1) was compared with the proportion at the ontreatment time-point 2 (T2). Despite a significant reduction in viral load at the second time-point, no significant change in nucleotide composition was observed for positions 1762, 1764, 1896, and 1899 between T1 and T2 (Fig. 4) .
3.5. Association of core promoter/precore mutations at baseline with therapy response 3.5.1. HBeAg-positive patients In HBeAg-positive patients, the presence of a 1764A and/or 1896A dominant mutation was associated with lower HBV-DNA (mean 6.93 vs 8.55 log 10 IU/mL, p ¼ 0.003), HBsAg (mean 3.76 vs 4.59 log 10 IU/mL, p ¼ 0.010), and HBeAg levels (mean 1.60 vs 3.03 log 10 IU/mL, p ¼ 0.009), compared to the presence of predominantly wild-type virus. However, no significant differences in the distribution of BCP or PC mutations were observed between HBeAg-positive patients with a combined response or nonresponse at week 72 (Table 2) .
HBeAg-negative patients
In HBeAg-negative patients, 17 non-responders (61%) had both mutations at position 1764 and 1896 whereas only 4 patients (29%) with a combined response at week 72 had both mutations (p < 0.05). In contrast, there was a trend of higher G1899A prevalence in HBeAg negative patients with a combined response compared to non-responders (non-reference 64% vs 36%, p ¼ 0.08). Interestingly, the 4 combined responders with both 1764 and 1896 mutations also harbored G1899A. No significant differences were observed between patients with HBsAg loss at week 144 and those who remained HBsAg positive.
HBeAg-negative patients with HBV genotype D had a higher prevalence of the 1764/1896 double mutation (75% vs 35%, p ¼ 0.011) as well as the G1899A mutation (69% vs 31%, p ¼ 0.016) at baseline. Corrected for genotype D in a multivariable logistic regression analysis, the 1764/1896 double mutation was strongly associated with lower ALT levels compared to patients with the single mutation (median ALT level 52 vs 110 U/L, p ¼ 0.004). Again applying correction for genotype D, the G1899A mutation was significantly associated with lower HBV DNA level (mean 5.15 vs 5.85 log IU/mL, p ¼ 0.036), higher age (mean 46.3 vs 41.0 years, p ¼ 0.030), and previous IFN therapy (53 vs 87% IFN naïve, p ¼ 0.032), compared to patients with 1899G.
Both the combination of 1764/1896 mutations and the presence of 1899A were independent predictors of a combined response in HBeAg-negative patients in different multivariable logistic regression models, including HBV genotype D vs non-D (Table 3) . Previously, baseline HBsAg was identified as an important predictor of response in HBeAg-negative patients in our study (Takkenberg et al., 2013) . Inclusion of these mutations into a logistic regression model including baseline HBsAg significantly improved the response classification accuracy (81%) compared to a model comprising only baseline HBsAg (p ¼ 0.003).
Discussion
In this study, we applied 454 ultra-deep pyrosequencing to study mutations in the basal core promoter (BCP) and precore (PC) region in 89 chronic hepatitis B patients (42 HBeAg-positive; 47 HBeAg-negative), both before and during treatment with Peg-IFN and adefovir. In an unbiased screen, the associations of 1762/1764 and 1896/1899 mutations with the HBeAg-negative phenotype were confirmed. Subsequently, strong and independent associations were observed between these mutations and treatment response in HBeAg-negative patients. In our study, all HBeAgnegative patients at least had one dominant mutation at position 1764 or 1896, whereas approximately half of the HBeAg-negative patients had dominant mutations at both positions. To our knowledge, this is the first study to report on the association of combined BCP and PC mutations with a decreased probability of achieving a combined response to IFN therapy. Furthermore, this is the only study that utilizes UDPS data, such as 454 DS, to study HBV variants in relation to (Peg-) IFN response.
Previous studies on the effect of PC and BCP mutations on IFNresponse were mostly limited to HBeAg-positive patients. While various studies associated an increased frequency of PC or BCP mutations before (Peg-)IFN-induced HBeAg seroconversion (Tseng et al., 2011; Chen et al., 2011; Tangkijvanich et al., 2009; Marrone et al., 2003; Erhardt et al., 2000) , a more recent study observed a lower probability of response in HBeAg-positive patients when BCP or PC mutations were present at baseline (Sonneveld et al., 2012) . Another recent study showed that detectable BCP and/or PC variants and increased viral diversity in HBeAg-positive patients exhibited a lower probability of HBsAg loss during long-term NA therapy (Bayliss et al., 2016) . Despite a strong association with markers of decreased viral replication (HBV-DNA, HBsAg and HBeAg), we did not find any significant associations with treatment response in HBeAg-positive patients. This lack of a significant difference may be explained by the limited number of HBeAg-positive patients in our study.
In contrast, we did observe significantly lower response rates in HBeAg-negative patients with combined BCP and PC mutations. At present, very limited data is available for HBeAg-negative patients. One previous study described a relatively smaller cohort of 32 HBeAg-negative patients treated with IFN-alpha (genotype A and D), in which sustained response correlated with the presence of wild-type sequence at position 1764 (but not 1896) by Sanger sequencing. No studies reported on the association of these mutations with HBsAg loss in HBeAg-negative patients. In our study no significant association for HBsAg loss was observed. Despite the high rate of HBsAg loss in our HBeAg-negative population, this may still be explained by the relatively limited number of patients achieving this outcome.
The lack of a combined presence of BCP and PC mutations, associated with increased response rates in HBeAg-negative patients, was strongly associated with increased baseline ALT levels as well. This is in line with previous studies in which ALT levels were reported to be higher in HBeAg-positive (Buster et al., 2009) and enegative (Bonino et al., 2007) patients who responded to peg-IFN therapy. Similarly, an intrahepatic signature of enhanced immune activity was observed in both HBeAg-positive and enegative responders from our cohort (Jansen et al., 2015) . These findings suggest that hepatocytes infected with HBV variants more closely related to wild-type HBV are more vulnerable to immune-mediated lysis than those infected with BCP and PC mutant variants (Chu et al., 2002) . Consequently, increased inflammatory activity at baseline appears to make these patients more susceptible to the immunomodulatory effect of IFN therapy. In contrast, the 1899A mutation was associated with increased response rates in HBeAg-negative patients. This mutation provides base pairing with nucleotide 1855T, thus enhancing the stability of the stem-loop structure. It is currently unknown why this mutation is associated with 1896A, nor why it mostly occurs later during infection (Lok et al., 1994) . In our cohort, patients with the 1899A mutation were significantly older and had lower HBV-DNA levels at baseline. Thus, this mutation may indeed reflect later stages of HBV infection in which viral adaptation to host immune pressure has further evolved at the expense of viral fitness. The observation that HBeAg-negative patients who were IFN-experienced were more likely to carry 1899A mutants, and the finding that previous IFNtreatment increased the chance of response in these patients (Takkenberg et al., 2013) , further underlines this hypothesis.
HBV variants that coexist as minorities with wild-type strains may have been missed in previous studies since they were mostly performed with direct sequencing methods. Next generation sequencing, such as 454 DS, is a powerful tool to detect these minority variants. The use of 454 DS allowed an unbiased and more sensitive screen of nucleotides located in the entire BCP and PC region, and their association with the HBeAg-negative phenotype. We confirmed the strong association of the BCP 1764 and PC 1896 mutations with the HBeAg-negative phenotype, depending on the presence of C1858 or T1858 (Chan et al., 1999 ). These welldescribed mutations explained the majority of HBeAg-negative cases, and additional mutations in this region appeared to play, at most, a minor role in determining HBeAg-negativity. Of note, since this study was limited to the BCP and PC region, the relative contribution of other regions of the HBV genome in relation to the HBeAg negative phenotype or IFN response was not determined, and should be subject of further investigation. Another important point of future research should focus on the contribution of different HBV genotypes on BCP and PC variability and IFN response. In our study we applied several genotype corrections, including the presence of HBV genotype D. However, both our HBeAg-positive and enegative cohorts consist of mixed HBV genotypes in which we could not extensively study the differential effects of each individual genotype.
Importantly, the availability of an on-treatment second sample allowed the quantitative analysis of these mutations during treatment. In one study 1896A was found to appear more frequently in patients with IFN-induced HBeAg loss (Tseng et al., 2011) . Another study, able to quantify BCP and PC mutant percentages, observed a significant increase in the percentage of PC mutation, but not that of BCP mutation, along the course of IFN-based therapy in patients achieving HBeAg loss (Yang et al., 2013) .
Interestingly, we observed no significant change in nucleotide composition during treatment, in both HBeAg-positive and enegative patients. This potentially contradicts the hypothesis of differential IFN sensitivity for BCP or PC variants and wild-type strains. However, the minimal amount of virus DNA needed to perform high-quality UDPS limited the opportunity to study HBV variants at later stages of treatment. The addition of adefovir to Peg-IFN treatment in our patients may have led to the earlier occurrence of this technical limitation.
Despite the fact that 454 DS has been shown to able to identify defective interfering particles, which may be regarded as a potential limitation of this technique, we did not identify such variants.
The absence of on-treatment HBV sequence dynamics highlights the relevance of baseline HBV variants as markers of response. Both the combination of 1764/1896 mutations and the presence of 1899A were independent predictors of a combined response in HBeAgnegative patients. Importantly, inclusion of these variables in multivariable logistic regression models significantly improved response classification accuracy.
With the advances in next-generation sequencing technologies, quantification of viral mutants is possible for decreasing costs. In this study, we used 454 UDPS to perform an in-depth analysis of viral diversity before and during therapy. Ultimately, we identified a combination of mutations that may be easily confirmed by conventional sequencing in other studies of HBeAg-negative patients treated with Peg-IFN based therapy. This makes large-scale production more feasible, and enables clinical utility for healthcare practitioners. Ultimately, the determination of HBV variant combinations identified in this study may guide the selection of those patients most likely to benefit from Peg-IFN-based treatment.
